Email Facebook Twitter

Member Info for bigbob0228

Send a private message to bigbob0228

Member Since: Mon, 7th Apr 2008

Number of Share Chat Posts (all time): 117
Number of Share Chat Posts (last 30 days): 0

Last Posted: 8 Oct '15

8 Oct '15

Yes enjoy
Q3 2015 Preliminary Production Results
Centamin is pleased to announce preliminary production results for the quarter ended 30 September
2015 from its Sukari Gold Mine (“Sukari”) in Egypt.
Preliminary total gold production for the quarter was 105,413 ounces, a 13% increase on Q3 2014 and
in line with production in the second quarter 2015. Full year production guidance of between 430,000
and 440,000 ounces is maintained.
Quarterly throughput at the process plant was 2,673kt, in line with Q2 2015 and with our previous
forecast and again in excess of the 10Mtpa nameplate capacity.
Open pit total material movement increased 5% on the previous quarter to 14,344kt with open pit ore
production increasing significantly on Q2 2015 by 26% to 2,204kt. The run of mine ore stockpile
balance decreased by 297kt to 1,030kt at the end of the period.
The underground operation delivered 312kt of ore, an 11% increase on Q2 2015.
Q3 2015 (preliminary) Q2 2015 Q3 2014
Open Pit - Total Material Movement (kt) 14,344 13,671 11,406
Open Pit - Ore Production (kt) 2,204 1,751 2,693
Underground Ore Production (kt) 312 282 248
Process Plant Throughput (kt) 2,673 2,667 2,388
Process Plant Productivity (tph) 1,342 1,361 1,252
Gold Produced (oz) 105,413 107,781 93,624
Andrew Pardey, CEO of Centamin, commented:
“Quarterly production was comparable with both the first and second quarters and in line with our
forecast for the period. Plant productivity remained above the 10Mtpa nameplate capacity and we
continue to expect further throughput increases as optimisation continues over the coming quarters.
The open pit and underground mining operations delivered an increase in material movement over
the previous quarter and with open pit grades set to increase towards the reserve average in the fourth
quarter, production guidance for the full year remains unchanged at between 430,000 and 440,000
For more information please contact:
Centamin plc
Josef El-Raghy, Chairman
Andrew Pardey, CEO
Andy Davidson, Head of Investor Relations
( +44 (0) 1534 828708
Bobby Morse, Robbie CeirogHughes
+ 44 (0) 20 7466 5000
18 Aug '15

this is now starting to look cheap will start buying at 325pps down to 300p for a nice two year investment.
GL All
6 Aug '15

GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
- FDA Orphan Designation Previously Granted -

LONDON, Aug. 6, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for a proprietary intravenous form of cannabidiol (CBD) to treat Neonatal Hypoxic-Ischemic Encephalopathy, or NHIE. In addition, the European Medicines Agency (EMA) has granted orphan designation for the same product to treat perinatal asphyxia, an alternate term that describes the same condition as NHIE, for which GW has already received Orphan Drug Designation from the FDA. There are currently no approved medicines in Europe or the U.S. specifically indicated for NHIE or perinatal asphyxia.
"GW believes that cannabinoids may have a potentially important role in the treatment of high need pediatric neurologic conditions. As a result, we have developed a proprietary intravenous CBD formulation specifically for use in this most vulnerable of patient populations, newborn infants with NHIE. As there are no current treatment options beyond induced hypothermia for the affected newborns, there exists a dramatic need to develop new and effective therapies aimed at preventing acute brain damage and enhancing long-term brain repair," stated Justin Gover, GW's Chief Executive Officer. "GW is now working towards the launch of a clinical development program in this important medical condition towards the end of this year."
NHIE and perinatal asphyxia are forms of acute or sub-acute brain injury due to asphyxia caused during the birth process and resulting from deprivation of oxygen during birth (hypoxia). The incidence of these conditions is estimated to be approximately 12,000 to 24,000 cases per year in the United States and EU combined. Of these cases, 35% are expected to die in early life and 30% may suffer from permanent disability. The current standard of care for perinatal asphyxia patients is to induce whole-body hypothermia. This treatment is only available in specialized neonatal intensive care units and must be started within 6 hours of birth. Even if a patient is put into induced hypothermia there is still a significant rate of morbidity and mortality, with a meta-analysis of the available data revealing a 27% death rate. Among the patients who survive, 28% suffer from major neurodevelopment issues and 26% develop Cerebral Palsy.
FDA's Fast Track program facilitates the development and review of drugs intended to treat serious conditions and fill an unmet medical need. A drug development program with Fast Track des
26 Mar '15

Just profit taking before April 5th
26 Mar '15

Nearly sh*t myself when price dropped to 6.2pps at 1119 lol

Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days

Member Login

Forgotten your password?


Don't have an account? Click here to Register Free!

Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.